Cholangiocarcinoma epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
Farima Kahe (talk | contribs) |
Farima Kahe (talk | contribs) (→Age) |
||
| Line 20: | Line 20: | ||
===Age=== | ===Age=== | ||
*Patients of all age groups may develop cholangiocarcinoma. | *Patients of all age groups may develop cholangiocarcinoma. | ||
*The median age at the time of cholangiocarcinoma diagnosis is 70-80 years, except in patients with bile duct cystic disorders. | *The median age at the time of cholangiocarcinoma diagnosis is 70-80 years, except in patients with bile duct cystic disorders.<ref name="Macias2014">{{cite journal|last1=Macias|first1=Rocio I. R.|title=Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives|journal=ISRN Hepatology|volume=2014|year=2014|pages=1–13|issn=2314-4041|doi=10.1155/2014/828074}}</ref> | ||
*Bile duct cystic disorders usually develop cholangiocarcinoma much earlier, between 30 and 40 years. | *Bile duct cystic disorders usually develop cholangiocarcinoma much earlier, between 30 and 40 years. | ||
Revision as of 15:56, 29 January 2018
|
Xyz Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cholangiocarcinoma epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Cholangiocarcinoma epidemiology and demographics |
|
Cholangiocarcinoma epidemiology and demographics in the news |
|
Risk calculators and risk factors for Cholangiocarcinoma epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Farima Kahe M.D. [2] Suveenkrishna Pothuru, M.B,B.S. [3]
Overview
Epidemiology and Demographics
Incidence
- The incidence of cholangiocarcinoma is approximately 1-2 per 100,000 individuals in the United States.
- The highest annual incidences of cholangiocarcinoma is 5.5 cases per 100,000 people in Japan, and 7.3 cases per 100,000 people in Israel.[1]
Prevalence
- The prevalence of cholangiocarcinoma is approximately 0.01% to 0.46% per 100,000 individuals.
- The prevalence of cholangiocarcinoma in patients with primary sclerosing cholangitis may be as high as 30%, based on autopsy studies.
Case-fatality rate/Mortality rate
- The mortality rate for intrahepatic cholangiocarcinoma among men increased from 0.17 to 0.78 per 100,000 in period of 1975-1979 to 1993-1997.[2]
- The mortality rate for intrahepatic cholangiocarcinoma among women women increased from 0.12 to 0.57 per 100,000 in period of 1975-1979 to 1993-1997.
Age
- Patients of all age groups may develop cholangiocarcinoma.
- The median age at the time of cholangiocarcinoma diagnosis is 70-80 years, except in patients with bile duct cystic disorders.[3]
- Bile duct cystic disorders usually develop cholangiocarcinoma much earlier, between 30 and 40 years.
Race
- Cholangiocarcinoma usually affects individuals of the American Indian, Alaska Natives and Asian and Pacific Islanders race.
Gender
- Cholangiocarcinoma is more common in males than in females.).[4]
Region
- The majority of cholangiocarcinoma cases are reported in North America, Asia, and Australia.[5]
References
- ↑ Khan SA, Toledano MB, Taylor-Robinson SD (2008). "Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma". HPB (Oxford). 10 (2): 77–82. doi:10.1080/13651820801992641. PMC 2504381. PMID 18773060.
- ↑ DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, Choti MA, Yeo CJ, Schulick RD (2007). "Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution". Ann. Surg. 245 (5): 755–62. doi:10.1097/01.sla.0000251366.62632.d3. PMC 1877058. PMID 17457168.
- ↑ Macias, Rocio I. R. (2014). "Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives". ISRN Hepatology. 2014: 1–13. doi:10.1155/2014/828074. ISSN 2314-4041.
- ↑ Cholangiocarcinoma. Radiopaedia. http://radiopaedia.org/articles/cholangiocarcinoma
- ↑ McLean L, Patel T (2006). "Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States". Liver Int. 26 (9): 1047–53. doi:10.1111/j.1478-3231.2006.01350.x. PMID 17032404.